Back

Potential for drug-drug interaction between vonoprazan and prasugrel on antiplatelet effect assessed by VerifyNow P2Y12 assay in patients with coronary artery disease

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 7 - Acute Coronary Syndromes - Treatment antiplatelet Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Seiji Koga

Juntendo University Nerima Hospital, Tokyo (Japan)

9 More presentations in this session

Presentation thumbnail
Ischemic and bleeding events during dual antiplatelet therapy after second-generation drug-eluting stent implantation in hemodialysis patients: a propensity score-matched analysis
Doctor A. Shimizu (Kitakyushu, JP)
Abstract
Presentation thumbnail
Predictors of bleeding in elderly patients with myocardial infarction: data from the real world
Doctor S. Alegria (Almada, PT)
Abstract
Presentation thumbnail
Myocardial infarction with nonobstructive coronary arteries: does aspirin have a place in the treatment of this entity?
Doctor J. Ferreira (Coimbra, PT)
Abstract
Presentation thumbnail
Platelet reactivity in Hepatitis C virus infected patients on dual antiplatelet therapy for acute coronary syndrome
Doctor F. Scudiero (Seriate, IT)
Abstract Slides
Presentation thumbnail
Potential benefit of ticagrelor monotherapy for patients with hypertension undergoing percutaneous coronary intervention: Insights from the Global Leaders trial
Doctor R. Modolo (Maple Grove, US)
Abstract

Access the full session

Session thumbnail
Poster Session 7 - Acute Coronary Syndromes - Treatment antiplatelet

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources